- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 791212, 11 pages
Mechanisms by Which Interleukin-6 Attenuates Cell Invasion and Tumorigenesis in Human Bladder Carcinoma Cells
1Department of Urology, Chang Gung Memorial Hospital, Kwei-Shan, Taoyuan 33305, Taiwan
2Bioinformation Center, Chang Gung Memorial Hospital, Kwei-Shan, Taoyuan 33305, Taiwan
3Department of Physiology, Collage of Medicine, Chang Gung University, Kwei-Shan, Taoyuan 33302, Taiwan
4Department of Anatomy, Collage of Medicine, Chang Gung University, Kwei-Shan, Taoyuan 33302, Taiwan
5School of Nursing, Collage of Medicine, Chang Gung University, Kwei-Shan, Taoyuan 33302, Taiwan
Received 25 March 2013; Accepted 23 April 2013
Academic Editor: Silvia Gregori
Copyright © 2013 Ke-Hung Tsui et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- Z. Culig, “Cytokine disbalance in common human cancers,” Biochimica et Biophysica Acta, vol. 1813, no. 2, pp. 308–314, 2011.
- C. G. Li, M. L. Li, X. H. Shu, Y. J. Liu, and W. S. Wu, “Antitumor effects of recombinant human Interleukin-6 on mouse bladder carcinoma through Fas-mediated apoptosis,” Cancer Chemotherapy and Pharmacology, vol. 66, no. 5, pp. 981–986, 2010.
- J. H. Han, M. Y. Lee, and S. C. Myung, “The effect of endothelin-1 on the production of interleukin-6 in cultured human detrusor smooth muscle cells, and the effect of interleukin-6 on the contractile response of bladder smooth muscle strips from rats,” The British Journal of Urology International, vol. 104, no. 5, pp. 707–712, 2009.
- T. I. Weng, Y. W. Hsiao, Y. L. Pei, and H. L. Shing, “Uropathogenic Escherichia coli-induced inflammation alters mouse urinary bladder contraction via an interleukin-6-activated inducible nitric oxide synthase-related pathway,” Infection and Immunity, vol. 77, no. 8, pp. 3312–3319, 2009.
- C. Escudero-Lourdes, M. K. Medeiros, M. C. Cárdenas-González, S. M. Wnek, and J. A. Gandolfi, “Low level exposure to monomethyl arsonous acid-induced the over-production of inflammation-related cytokines and the activation of cell signals associated with tumor progression in a urothelial cell model,” Toxicology and Applied Pharmacology, vol. 244, no. 2, pp. 162–173, 2010.
- A. Agarwal, U. Agrawal, S. Verma, N. K. Mohanty, and S. Saxena, “Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre-and post-intravesical combination immunotherapy,” Immunopharmacology and Immunotoxicology, vol. 32, no. 2, pp. 348–356, 2010.
- F. H. Chen, S. A. Crist, G. J. Zhang, Y. Iwamoto, and W. A. See, “Interleukin-6 production by human bladder tumor cell lines is up-regulated by bacillus Calmette-Guerin through nuclear factor-κB and AP1-1 via an immediate early pathway,” Journal of Urology, vol. 168, no. 2, pp. 786–797, 2002.
- F. Chen, G. Zhang, Y. Cao, M. J. Hessner, and W. A. See, “MB49 murine urothelial carcinoma: molecular and phenotypic comparison to human cell lines as a model of the direct tumor response to bacillus Calmette-Guerin,” Journal of Urology, vol. 182, no. 6, pp. 2932–2937, 2009.
- C. M. Bailey, Z. Khalkhali-Ellis, E. A. Seftor, and M. J. C. Hendrix, “Biological functions of maspin,” Journal of Cellular Physiology, vol. 209, no. 3, pp. 617–624, 2006.
- S. Sugimoto, N. Maass, Y. Takimoto et al., “Expression and regulation of tumor suppressor gene maspin in human bladder cancer,” Cancer Letters, vol. 203, no. 2, pp. 209–215, 2004.
- M. G. Friedrich, M. I. Toma, S. Petri et al., “Expression of maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis,” European Urology, vol. 45, no. 6, pp. 737–743, 2004.
- E. Juengel, W. D. C. Beecken, S. Mundiyanapurath, T. Engl, D. Jonas, and R. A. Blaheta, “Maspin modulates adhesion of bladder carcinoma cells to vascular endothelium,” World Journal of Urology, vol. 28, no. 4, pp. 465–471, 2010.
- H. M. Romanska and F. Berditchevski, “Tetraspanins in human epithelial malignancies,” Journal of Pathology, vol. 223, no. 1, pp. 4–14, 2011.
- Y. Yu, J. L. Yang, B. Markovic et al., “Loss of KAI1 messenger RNA expression in both high-grade and invasive human bladder cancers,” Clinical Cancer Research, vol. 3, no. 7, pp. 1045–1049, 1997.
- P. Jackson, E. A. Kingsley, and P. J. Russell, “Inverse correlation between KAI1 mRNA levels and invasive behaviour in bladder cancer cell lines,” Cancer Letters, vol. 156, no. 1, pp. 9–17, 2000.
- V. Melotte, X. Qu, M. Ongenaert et al., “The N-myc downstream regulated gene (NDRG) family: diverse functions, multiple applications,” FASEB Journal, vol. 24, no. 11, pp. 4153–4166, 2010.
- J. P. Thiery, H. Acloque, R. Y. J. Huang, and M. A. Nieto, “Epithelial-mesenchymal transitions in development and disease,” Cell, vol. 139, no. 5, pp. 871–890, 2009.
- J. P. Their, “Epithelial-mesenchymal transitions in tumor progression,” Nature Reviews Cancer, vol. 2, no. 6, pp. 442–454, 2002.
- M. Sabbah, S. Emami, G. Redeuilh et al., “Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers,” Drug Resistance Updates, vol. 11, no. 4-5, pp. 123–151, 2008.
- J. M. Lee, S. Dedhar, R. Kalluri, and E. W. Thompson, “The epithelial-mesenchymal transition: new insights in signaling, development, and disease,” Journal of Cell Biology, vol. 172, no. 7, pp. 973–981, 2006.
- T. Jäger, M. Becker, A. Eisenhardt et al., “The prognostic value of cadherin switch in bladder cancer,” Oncology Reports, vol. 23, no. 4, pp. 1125–1132, 2010.
- K. H. Tsui, Y. F. Lin, Y. H. Chen, P. L. Chang, and H. H. Juang, “Mechanisms by which interleukin-6 regulates prostate-specific antigen gene expression in prostate LNCaP carcinoma cells,” Journal of Andrology, vol. 32, no. 4, pp. 383–393, 2011.
- L. C. Chung, K. H. Tsui, T. H. Feng, S. L. Lee, P. L. Chang, and H. H. Juang, “L-Mimosine blocks cell proliferation via upregulation of B-cell translocation gene 2 and N-myc downstream regulated gene 1 in prostate carcinoma cells,” The American Journal of Physiology, vol. 302, no. 4, pp. C676–C685, 2012.
- K. H. Tsui, Y. L. Chang, T. H. Feng et al., “Growth differentiation factor-15 upregulates interleukin-6 to promote tumorigenesis of prostate carcinoma PC-3 cells,” Journal of Molecular Endocrinology, vol. 49, no. 2, pp. 153–163, 2012.
- L. C. Chung, K. H. Tsui, T. H. Feng, S. L. Lee, P. L. Chang, and H. H. Juang, “Curcumin provides potential protection against the activation of hypoxia and prolyl 4-hydroxylase inhibitors on prostate-specific antigen expression in human prostate carcinoma cells,” Molecular Nutrition and Food Research, vol. 55, no. 11, pp. 1666–1676, 2011.
- K. H. Tsui, Y. L. Chang, T. H. Feng, P. L. Chang, and H. H. Juang, “Glycoprotein transmembrane nmb: an androgen-downregulated gene attenuates cell invasion and tumorigenesis in prostate carcinoma cells,” Prostate, vol. 72, no. 13, pp. 1431–1442, 2012.
- K. H. Tsui, L. C. Chung, T. H. Feng, P. L. Chang, and H. H. Juang, “Upregulation of prostate-derived Ets factor by luteolin causes inhibition of cell proliferation and cell invasion in prostate carcinoma cells,” International Journal of Cancer, vol. 130, no. 12, pp. 2812–2823, 2012.
- H. H. Juang, Y. F. Lin, P. L. Chang, and K. H. Tsui, “Cardiac glycosides decrease prostate specific antigen expression by down-regulation of prostate derived Ets factor,” Journal of Urology, vol. 184, no. 5, pp. 2158–2164, 2010.
- B. Andrews, S. F. Shariat, J. H. Kim, T. M. Wheeler, K. M. Slawin, and S. P. Lerner, “Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer,” Journal of Urology, vol. 167, no. 3, pp. 1475–1481, 2002.
- T. Cai, S. Mazzoli, F. Meacci et al., “Interleukin-6/10 ratio as a prognostic marker of recurrence in patients with intermediate risk urothelial bladder carcinoma,” Journal of Urology, vol. 178, no. 5, pp. 1906–1911, 2007.
- A. Agarwal, S. Verma, U. Burra, N. S. Murthy, N. K. Mohanty, and S. Saxena, “Flow cytometric analysis of Th1 and Th2 cytokines in PBMCs as a parameter of immunological dysfunction in patients of superficial transitional cell carcinoma of bladder,” Cancer Immunology, Immunotherapy, vol. 55, no. 6, pp. 734–743, 2006.
- C. C. Rigby and L. M. Franks, “A human tissue culture cell line from a transitional cell tumour of the urinary bladder: growth, chromosone pattern and ultrastructure,” The British Journal of Cancer, vol. 24, no. 4, pp. 746–754, 1970.
- S. Rasheed, M. B. Gardner, and R. W. Rongey, “Human bladder carcinoma: characterization of two new tumor cell lines and search for tumor viruses,” Journal of the National Cancer Institute, vol. 58, no. 4, pp. 881–890, 1977.
- J. Bubenik, M. Baresova, V. Viklicky, J. Jakoubkova, H. Sainerova, and J. Donner, “Established cell line of urinary bladder carcinoma (T24) containing tumour specific antigen,” International Journal of Cancer, vol. 11, no. 3, pp. 765–773, 1973.
- K. G. Steube, C. Meyer, and H. G. Drexler, “Secretion of functional hematopoietic growth factors by human carcinoma cell lines,” International Journal of Cancer, vol. 78, no. 1, pp. 120–124, 1998.
- F. R. Santer, K. Malinowska, Z. Culig, and I. T. Cavarretta, “Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells,” Endocrine-Related Cancer, vol. 17, no. 1, pp. 241–253, 2010.
- Z. Culig, H. Steiner, G. Bartsch, and A. Hobisch, “Interleukin-6 regulation of prostate cancer cell growth,” Journal of Cellular Biochemistry, vol. 95, no. 3, pp. 497–505, 2005.
- Z. Kovacevic and D. R. Richardson, “The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer,” Carcinogenesis, vol. 27, no. 12, pp. 2355–2366, 2006.
- T. P. Ellen, Q. Ke, P. Zhang, and M. Costa, “NDRG1, a growth and cancer related gene: regulation of gene expression andfunction in normal and disease states,” Carcinogenesis, vol. 29, no. 1, pp. 2–8, 2008.
- R. Røtterud, S. D. Fosså, and J. M. Nesland, “Protein networking in bladder cancer: immunoreactivity for FGFR3, EGFR, ERBB2, KAI1, PTEN, and RAS in normal and malignant urothelium,” Histology and Histopathology, vol. 22, no. 4-6, pp. 349–363, 2007.
- M. E. Fondrevelle, B. Kantelip, R. E. Reiter et al., “The expression of Twist has an impact on survival in human bladder cancer and is influenced by the smoking status,” Urologic Oncology: Seminars and Original Investigations, vol. 27, no. 3, pp. 268–276, 2009.
- F. Bruyere, B. Namdarian, N. M. Corcoran et al., “Snail expression is an independent predictor of tumor recurrence in superficial bladder cancers,” Urologic Oncology: Seminars and Original Investigations, vol. 28, no. 6, pp. 591–596, 2010.
- D. J. McConkey, S. Lee, W. Choi et al., “Molecular genetics of bladder cancer: emerging mechanisms of tumor initiation and progression,” Urologic Oncology: Seminars and Original Investigations, vol. 28, no. 4, pp. 429–440, 2010.
- P. A. Kenney, M. F. Wszolek, K. M. Rieger-Christ et al., “Novel ZEB1 expression in bladder tumorigenesis,” The British Journal of Urology International, vol. 107, no. 4, pp. 656–663, 2011.
- Z. Cai, Y. Zhou, T. Lei, J. F. Chiu, and Q. Y. He, “Mammary serine protease inhibitor inhibits epithelial growth factor-induced epithelial-mesenchymal transition of esophageal carcinoma cells,” Cancer, vol. 115, no. 1, pp. 36–48, 2009.
- S. K. Kachhap, D. Faith, D. Z. Qian et al., “The N-Myc down regulated gene1 (NDRG1) is a Rab4a effector involved in vesicular recycling of E-cadherin,” PLoS ONE, vol. 2, no. 9, article e844, 2007.
- Y. Song, Y. Oda, M. Hori et al., “N-myc downstream regulated gene-1/Cap43 may play an important role in malignant progression of prostate cancer, in its close association with E-cadherin,” Human Pathology, vol. 41, no. 2, pp. 214–222, 2010.